The aim of this study was to determine aztreonam (ATM) membrane permeability using Calu-3 cells and its plasma and pulmonary epithelial lining fluid (ELF) pharmacokinetics in rats after intratracheal nebulization and intravenous administration (15 mg · kg(-1)). ATM exhibits low Calu-3 permeability (0.07 ± 0.02 × 10(-6) cm · s(-1)), and a high area under the ELF/unbound plasma concentration time curve between 0 and infinity (AUCELF/AUCu,plasma) ratio of 1,069 was observed after nebulization in rats. These results confirm that ATM is a low-permeability molecule and a good candidate for nebulization.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862445 | PMC |
http://dx.doi.org/10.1128/AAC.00165-16 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!